![]() He joins ADC Therapeutics from ClearView Healthcare Partners, a global strategy and consulting firm focused on life sciences, where he played a key role in direct client service as well as global expansion efforts helping his clients accomplish significant business development and strategic transactions from 2019-2022. At Novartis, he was Global Head of Portfolio Strategy and Business Development for Novartis Oncology, from 2018-2019. Gilman is a pharmaceutical business executive with over 25 years of experience. “We are excited to have David join our leadership team at this pivotal moment in the evolution of ADC Therapeutics.” “David Gilman is a seasoned business development and strategy executive who has an excellent track record within the life sciences industry,” said Ameet Mallik, President and Chief Executive Officer of ADC Therapeutics. Gilman will be responsible for all business development and portfolio strategy efforts globally and he will serve on the Company’s executive leadership team. ![]() Mallik, Ameet (ADC Therapeutics 202205– CEO before Rafael Holdings + 16y at Novartis + McKinsey & Co)ĪDC Therapeutics SA (NYSE: ADCT) announced today it has appointed industry veteran David Gilman to the new role of Chief Business & Strategy Officer reporting to Chief Executive Officer Ameet Mallik effective July 1st. Gilman, David (ADC Therapeutics 202206– Chief Business + Strategy Officer before ClearView Healthcare Partners) Lausanne.Īntibody-drug conjugates (ADC) technology ![]() ![]() "Press Release: ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer". ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |